HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety.

AbstractOBJECTIVE:
Suicide is a psychiatric emergency. Currently, there are no approved pharmacologic treatments for suicidal ideation. Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist that rapidly reduces suicidal ideation as well as depression and anxiety, but the dynamic between these symptoms is not known. The aim of this analysis was to evaluate whether ketamine has an impact on suicidal thoughts, independent of depressive and anxiety symptoms.
METHODS:
133 patients with treatment-resistant depression (major depressive disorder or bipolar I/II disorder) received a single subanesthetic infusion of ketamine (0.5 mg/kg over 40 min). Post-hoc correlations and linear mixed models evaluated the relationship between suicidal ideation and depression and anxiety symptoms using the Hamilton Depression Rating Scale (HAMD), Scale for Suicidal Ideation (SSI), Beck Depression Inventory (BDI), and Hamilton Anxiety Rating Scale (HAMA) focusing on 230 min post-infusion.
RESULTS:
At 230 min post-infusion, correlations between changes in suicidal ideation and depression ranged from 0.23 to 0.44 (p < .05), accounting for up to 19% in the variance of ideation change. Correlations with anxiety ranged from 0.23 to 0.40 (p < .05), accounting for similar levels of variance. Ketamine infusion was associated with significant reductions in suicidal ideation compared to placebo, when controlling for the effects of ketamine on depression (F1,587 = 10.31, p = .001) and anxiety (F1,567 = 8.54, p = .004).
CONCLUSIONS:
Improvements in suicidal ideation after ketamine infusion are related to, but not completely driven by, improvements in depression and anxiety. Investigation of the specific effects of ketamine on suicidal thoughts is warranted.
AuthorsElizabeth D Ballard, Dawn F Ionescu, Jennifer L Vande Voort, Mark J Niciu, Erica M Richards, David A Luckenbaugh, Nancy E Brutsché, Rezvan Ameli, Maura L Furey, Carlos A Zarate Jr
JournalJournal of psychiatric research (J Psychiatr Res) Vol. 58 Pg. 161-6 (Nov 2014) ISSN: 1879-1379 [Electronic] England
PMID25169854 (Publication Type: Clinical Trial, Journal Article, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't)
CopyrightPublished by Elsevier Ltd.
Chemical References
  • Analgesics
  • Ketamine
Topics
  • Adolescent
  • Adult
  • Aged
  • Analgesics (therapeutic use)
  • Depression (drug therapy, psychology)
  • Female
  • Humans
  • Infusions, Subcutaneous
  • Ketamine (therapeutic use)
  • Male
  • Middle Aged
  • Psychiatric Status Rating Scales
  • Statistics as Topic
  • Suicidal Ideation
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: